NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Sees Large Drop in Short Interest
by Danessa Lincoln · The Markets DailyNLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 2,191 shares, a drop of 94.8% from the December 15th total of 41,855 shares. Based on an average daily volume of 42,567 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company’s shares are sold short. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 42,567 shares, the short-interest ratio is currently 0.1 days.
NLS Pharmaceutics Stock Performance
NASDAQ NCEL traded up $0.30 during mid-day trading on Monday, hitting $2.49. The company’s stock had a trading volume of 2,222,010 shares, compared to its average volume of 78,039. The company’s 50 day simple moving average is $3.18 and its 200 day simple moving average is $14.44. NLS Pharmaceutics has a twelve month low of $1.89 and a twelve month high of $33.70.
Wall Street Analysts Forecast Growth
NCEL has been the topic of a number of research analyst reports. Wall Street Zen cut NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of NLS Pharmaceutics in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on NLS Pharmaceutics
NLS Pharmaceutics Company Profile
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.